Evidence map›Paper›PMID 31668804›Full record

ArticleCell2019

Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.

Eytan Herzig, Kaman Chan Kim, Thomas A Packard, Noam Vardi, Roland Schwarzer, Andrea Gramatica, Steven G Deeks, Steven R Williams, Kyle Landgraf, Nigel Killeen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. HIV Cure: How Far We Have Come?Indian journal of microbiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Recent advances in CD8Heliyon · 2023
    Review
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eytan HerzigGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kaman Chan KimXyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
Thomas A PackardGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Noam VardiGladstone Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Departments of Biochemistry and Biophysics and Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
Roland SchwarzerGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Andrea GramaticaGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
Steven R WilliamsXyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
Kyle LandgrafXyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
Nigel KilleenXyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
David W MartinXyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
Leor S WeinbergerGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Gladstone Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Departments of Biochemistry and Biophysics and Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
Warner C GreeneGladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: warner.greene@gladstone.ucsf.edu.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
Evolvable 'Resistance-Proof' TherapiesDP1DE024408 · NIDCR · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2013 to 2017
$4.8M
Stochastic Gene Expression in Retroviral LatencyR01AI109593 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2014 to 2018
$2.2M
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI109593NIDCR NIH HHS DP1 DE024408
6 · The paper itself

Abstract

Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells to become visible to the immune system. A critical second step is killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the evolution of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, convertibleCAR-T cells, effectively kills HIV-infected, but not uninfected, CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies. convertibleCAR-T cells also kill within 48 h more than half of the inducible reservoir found in blood of HIV-infected individuals on antiretroviral therapy. The modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.

Indexed as

Immunotherapy, AdoptiveAnimalsAntibodies, Anti-IdiotypicHEK293 CellsHIV-1HIV InfectionsHumansMicePalatine TonsilPrimary Cell CultureSpleenT-Lymphocytes, CytotoxicVirus LatencyVirus ReplicationAntibodies, Anti-IdiotypicbNAbbroadly neutralizing HIV antibodiesCAR-TconvertibleCAR-THIV latencyMicAbodyreduce-and-controlreservoirshock-and-killT cell therapy

Identifiers

PMID31668804
PMCPMC6922308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.